Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 2Thoracic 1Plasma cell 1Other solid neoplasm 1Genitourinary 1

Conditions

Renal Pelvis and Ureter Urothelial Carcinoma 1

Interventions

Magnetic Resonance Spectroscopy 63Specimen Handling 58pembrolizumab 40enzalutamide 38Nivolumab 32Gemcitabine 30Docetaxel 28Biopsy 25Prednisone 23Abiraterone Acetate 21apalutamide 20Androgen Antagonists 19Radiosurgery 18Cisplatin 18darolutamide 16cabozantinib 16abiraterone 16Radiotherapy 16enfortumab vedotin 15Radiation 14Ipilimumab 13belzutifan 12Pluvicto 12Mitomycin 12olaparib 11erdafitinib 11durvalumab 11atezolizumab 11X-Rays 10Standard of Care 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
pegylated granulocyte colony-stimulating factor × Genitourinary × 30 days × Clear all
NCT04628767 2026-06-03

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

National Cancer Institute (NCI)

Phase 2/3 Recruiting
131 enrolled
Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡